Patents Assigned to Eisai, Inc.
-
Patent number: 8329666Abstract: Provided herein are methods of treating cancer comprising administering decitabine in combination with compounds that inhibit the deamination enzyme responsible for the inactivation of decitabine.Type: GrantFiled: April 6, 2010Date of Patent: December 11, 2012Assignee: Eisai Inc.Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
-
Patent number: 8329665Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.Type: GrantFiled: April 6, 2010Date of Patent: December 11, 2012Assignee: Eisai Inc.Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
-
Publication number: 20120309717Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.Type: ApplicationFiled: February 1, 2012Publication date: December 6, 2012Applicant: EISAI INC.Inventors: Vincent J. Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy Dongxia Xing, Qun Liu
-
Patent number: 8324180Abstract: Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.Type: GrantFiled: April 6, 2010Date of Patent: December 4, 2012Assignee: Eisai Inc.Inventors: Sergei Belyakov, Bridget Duvall, Dana Ferraris, Gregory Hamilton, Mark Vaal
-
Patent number: 8268800Abstract: The present invention provides certain tetrahydrouridine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of making and using such compounds.Type: GrantFiled: October 16, 2008Date of Patent: September 18, 2012Assignee: Eisai Inc.Inventors: Gregory S. Hamilton, Takashi Tsukamoto, Dana V. Ferraris, Bridget Duvall, Rena Lapidus
-
Patent number: 8258255Abstract: The present invention relates to novel phosphorus-containing compounds with polymeric chains, and methods of making and using the same. In part, subject compositions containing phosphorus-containing compounds with polymeric chains and a therapeutic agent, and methods of making and using the same, are described. Certain of the subject compositions exhibit reverse thermal gelation.Type: GrantFiled: January 22, 2010Date of Patent: September 4, 2012Assignee: Eisai Inc.Inventors: Keith Branham, Mahesh V. Chaubal, James P. English, Donna Hall, Zhong Zhao
-
Publication number: 20120201843Abstract: The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.Type: ApplicationFiled: March 19, 2012Publication date: August 9, 2012Applicant: Eisai, Inc.Inventors: Nazneen Aziz, Mary Lynne Hedley, Robert G. Urban, Andrew J. Tomlinson, Geoffrey Cole
-
Patent number: 8236802Abstract: The present invention relates to tetraaza phenalen-3-one compounds which inhibit poly (ADP-ribose) polymerase (PARP) and are useful in the chemosensitization of cancer therapeutics. The induction of peripheral neuropathy is a common side-effect of many of the conventional and newer chemotherapies. The present invention further provides means to reliably prevent or cure chemotherapy-induced neuropathy. The invention also relates to the use of the disclosed PARP inhibitor compounds in enhancing the efficacy of chemotherapeutic agents such as temozolomide. The invention also relates to the use of the disclosed PARP inhibitor compounds to radiosensitize tumor cells to ionizing radiation. The invention also relates to the use of the disclosed PARP inhibitor compounds for treatment of cancers with DNA repair defects.Type: GrantFiled: October 2, 2008Date of Patent: August 7, 2012Assignee: Eisai Inc.Inventors: Weizheng Xu, Greg Delahanty, Ling Wei, Jie Zhang
-
Publication number: 20120171289Abstract: The invention features a composition for the delivery of bioactive agents into cells that includes a delivery matrix, an anionic or zwitterionic compound, and a bioactive agent, e.g. a peptide, protein, or nucleic acid. The compositions of the invention can be used to deliver bioactive compounds, such as nucleic acids encoding immunostimulatory peptides and/or therapeutic proteins.Type: ApplicationFiled: March 24, 2010Publication date: July 5, 2012Applicant: EISAI INC.Inventors: Shikha P. Barman, Una McKeever, Mary Lynne Hedley
-
Publication number: 20120115873Abstract: The present invention relates to diazabenzo[de]anthracen-3.-onei compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.Type: ApplicationFiled: September 27, 2011Publication date: May 10, 2012Applicant: EISAI INC.Inventors: Weizheng XU, Greg Delahanty, Jie Zhang
-
Patent number: 8158594Abstract: The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.Type: GrantFiled: April 30, 2007Date of Patent: April 17, 2012Assignee: Eisai Inc.Inventors: Nazneen Aziz, Mary Lynne Hedley, Robert G. Urban, Andrew J. Tomlinson, Geoffrey Cole
-
Patent number: 8129407Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R7, X1, X2, R, Q, and n are as defined herein.Type: GrantFiled: February 27, 2009Date of Patent: March 6, 2012Assignee: Eisai Inc.Inventors: James J. Kowalczyk, Galina Kuznetsov, Shawn Schiller, Boris M. Seletsky, Mark Spyvee, Hu Yang
-
Patent number: 8129382Abstract: The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.Type: GrantFiled: June 18, 2010Date of Patent: March 6, 2012Assignee: Eisai Inc.Inventors: Vincent Kalish, Jie Zhang, Weizheng Xu, Jia-He Li, Amy D. Xing, Qun Liu
-
Patent number: 8058275Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.Type: GrantFiled: October 22, 2010Date of Patent: November 15, 2011Assignee: Eisai Inc.Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
-
Publication number: 20110251239Abstract: Provided herein is a combination therapy useful for the treatment of Alzheimer's disease and Alzheimer's disease related dementia. The combination comprises memantine in an immediate or sustained release form and donepezil in a sustained release form.Type: ApplicationFiled: April 7, 2011Publication date: October 13, 2011Applicant: EISAI INC.Inventors: Margaret Lynn MOLINE, James FERRY, Timothy HSU, Lynn Darden KRAMER, Andrew SATLIN
-
Publication number: 20110166112Abstract: Provided are methods for increasing platelet response in a subject at risk for bleeding due at least in part to a low platelet count by administering to a subject with a low platelet count an effective amount of 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridine-2-yl)piperidine-4-carboxylic acid.Type: ApplicationFiled: August 13, 2010Publication date: July 7, 2011Applicant: Eisai, Inc.Inventor: Yanzhen Zhang
-
Publication number: 20110158952Abstract: The invention includes methods of treating an HPV-mediated disease by administration to an individual of a pharmaceutical composition comprising a nucleic acid that encodes a polypeptide comprising an epitope of a naturally occurring HPV protein. The methods include the selection of individuals for treatment with the composition according to a the age of the recipient, as well as the use of the composition to elicit a cross-reactive anti-HPV immune response.Type: ApplicationFiled: June 7, 2010Publication date: June 30, 2011Applicant: EISAI INC.Inventors: Kathleen Beach, Mary Lynne Hedley, Robert G. Urban, Roman M. Chicz
-
Patent number: 7968593Abstract: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-? activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy, pain, a prostate disease, cancer, Huntington's disease, diabetes, a retinal disorder or glaucoma.Type: GrantFiled: May 26, 2009Date of Patent: June 28, 2011Assignee: Eisai Inc.Inventors: Barbara S. Slusher, Takashi Tsukamoto
-
Publication number: 20110092478Abstract: The present invention relates to diazabenzo[de]anthracen-3-one compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat, prevent and/or ameliorate the effects of the conditions described herein.Type: ApplicationFiled: October 22, 2010Publication date: April 21, 2011Applicant: Eisai Inc.Inventors: Weizheng Xu, Greg Delahanty, Jie Zhang
-
Patent number: 7915280Abstract: This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.Type: GrantFiled: August 30, 2005Date of Patent: March 29, 2011Assignee: Eisai Inc.Inventors: Dana Victor Ferraris, Jia-He Li, Vincent Kalish, Jie Zhang